Glycopyrrolate, an anticholinergic, and formoterol fumarate, a long-acting beta2-adrenergic agonist (LABA), are indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Not indicated for the relief of acute bronchospasm or for the treatment of asthma.
১০০% অরিজিনাল পণ্যের নিশ্চয়তা
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Glycopyrrolate: Glycopyrrolate is a long-acting antimuscarinic agent that is often referred to as an anticholinergic. It has similar affinity for the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of the M3 receptor at the smooth muscle, leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal-origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo studies, prevention of methylcholine and acetylcholine-induced bronchoconstrictive effects was dose-dependent and lasted more than 12 hours. The clinical relevance of these findings is unknown. The bronchodilation following inhalation of glycopyrrolate is predominantly a site-specific effect.
Formoterol Fumarate: Formoterol fumarate is a long-acting selective beta2-adrenergic agonist (beta2-agonist) with a rapid onset of action. Inhaled formoterol fumarate acts locally in the lung as a bronchodilator. In vitro studies have shown that formoterol has more than 200-fold greater agonist activity at beta2-receptors than at beta1-receptors. The in vitro binding selectivity to beta2- over beta1 adrenoceptors is higher for formoterol than for albuterol (5 times), whereas salmeterol has a higher (3 times) beta2-selectivity ratio than formoterol. Although beta2-receptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-receptors are the predominant receptors in the heart, there are also beta2 receptors in the human heart comprising 10% to 50% of the total beta-adrenergic receptors. The precise function of these receptors has not been established, but they raise the possibility that even highly selective beta2-agonists may have cardiac effects.
You are advised not to consume alcohol while taking Formoterol+glycopyrrolate, as it might cause increased dizziness.
Please consult your doctor if you have any concerns regarding this; your doctor will prescribe only if the benefits outweigh the risks.
Consult your doctor if you are breastfeeding; your doctor will decide whether breastfeeding mothers can take Formoterol+glycopyrrolate or not.
Formoterol+glycopyrrolate may cause dizziness. Drive or operate machinery only if you are alert.
Inform your doctor if you have kidney disease before using Formoterol+glycopyrrolate. Your doctor will determine potential risks before prescribing.
Inform your doctor if you have liver disease before using Formoterol+glycopyrrolate. Your doctor will determine potential risks before prescribing.
ওয়েবসাইট থেকে অর্ডার করার সহজ ভিডিও গাইড।
অ্যাপ থেকে অর্ডারের সহজ ভিডিও গাইড
অ্যাপ ডাউনলোডePharma অ্যাপ ডাউনলোড বিস্তারিত গাইড ›অ্যাপে অর্ডারের বিস্তারিত গাইডThis inhaler should be administered as two inhalations taken twice daily in the morning and in the evening by the oral inhalation route only. Do not take more than two inhalations twice daily.
This inhaler contains 120 inhalations per canister. The canister has an attached dose indicator, which indicates how many inhalations remain. The dose indicator display will move after every tenth actuation. When nearing the end of the usable inhalations, the color behind the number in the dose indicator display window changes to red. This inhaler should be discarded when the dose indicator display window shows zero.
Priming this inhaler is essential to ensure appropriate drug content in each actuation. Prime this inhaler before using for the first time. To prime this inhaler, release 4 sprays into the air away from the face, shaking well before each spray. This inhaler must be re-primed when the inhaler has not been used for more than 7 days. To re-prime this inhaler, release 2 sprays into the air away from the face, shaking well before each spray.
Pregnancy Category C. There are no adequate and well-controlled trials of this inhaler or its individual components, glycopyrrolate and formoterol fumarate, in pregnant women. Because animal reproduction studies are not always predictive of human response, this inhaler should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Women should be advised to contact their physicians if they become pregnant while taking this inhaler.
It is not known whether this inhaler is excreted in human milk. Because many drugs are excreted in human milk and because formoterol fumarate, one of the active ingredients in this inhaler, has been detected in the milk of lactating rats, caution should be exercised when this inhaler is administered to a nursing woman. Since there are no data from controlled trials on the use of this inhaler by nursing mothers, a decision should be made whether to discontinue nursing or to discontinue this inhaler, taking into account the importance of this inhaler to the mother.
Pressurized canister; do not puncture, break, or incinerate even when empty, as the canister may explode. Avoid exposure to direct sunlight or heat. Clean your inhaler regularly as per directions. Do not store above 30° C. Keep in a dry place. Protect from light and keep out of the reach of children. Keep away from eyes. Discard within three months after removing from the foil pouch. For best results, the canister should be at room temperature before use. Shake well before each use.
⚠️Disclaimer:
At ePharma, we’re committed to providing accurate and accessible health information. However, all content is intended for informational purposes only and should not replace medical advice from a qualified physician. Please consult your healthcare provider for personalized guidance. We aim to support, not substitute, the doctor-patient relationship.